<DOC>
	<DOCNO>NCT01202149</DOCNO>
	<brief_summary>This investigator-blinded , bilateral comparison study 30 subject atopic dermatitis . It design assess compare efficacy Elidel® ( pimecrolimus ) cream 1 % Hylatopic™ Plus Emollient Foam™ subject atopic dermatitis . Subjects apply Elidel® ( pimecrolimus ) cream 1 % twice daily four week choose target eczematous area locate one side body apply Hylatopic™ Plus Emollient Foam™ three time daily symmetrical target eczematous area opposite side body . A randomized list create determine side subject applies medication . Subjects consent prior study evaluation procedure . After sign consent meeting inclusion/exclusion criterion , qualify enrolled subject apply study medication ( Elidel® Hylatopic™ Plus Emollient Foam™ ) chosen affect area four week . Photography use record location target lesion baseline , week two week four/final visit . Subject 's disease status assess two method : 1 ) Physician 's Global Assessment ( PGA ) 2 ) Target Lesion Symptom Score ( TLSS ) ( see section V.B.2 V.B.3 ) . PGA well TLSS make baseline ( Day 0 ) , week two ( Day 14 +/- 2 day ) week 4/final visit ( Day 28 +/- 2days ) visit target lesion . Half scale ( i.e . 0.5 , 1.5 ) use . The presence absence skin atrophy telangiectasias note study visit well . Additionally , subject ' self-assessments perception degree disease itch severity control collect visit target lesion . This assessment make use four point scale Itch Severity Scale ( visual analogue score ) respectively ( see section V.B.4 ) . Lastly , subject take Product Preference Survey week 4/final visit ( Day 28 +/- 2days ) . Parents ( guardian ) moderate Product Preference Surveys subject young 12 year age .</brief_summary>
	<brief_title>Bilateral Comparison Study Elidel 1 % Hylatopic Plus Emollient Foam Treatment Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This investigator-blinded , bilateral comparison study 30 subject atopic dermatitis . It design assess compare efficacy Elidel® ( pimecrolimus ) cream 1 % Hylatopic™ Plus Emollient Foam™ subject atopic dermatitis . Subjects apply Elidel® ( pimecrolimus ) cream 1 % twice daily four week choose target eczematous area locate one side body apply Hylatopic™ Plus Emollient Foam™ three time daily symmetrical target eczematous area opposite side body . A randomized list create determine side subject applies medication . Subjects consent prior study evaluation procedure . After sign consent meeting inclusion/exclusion criterion , qualify enrolled subject apply study medication ( Elidel® Hylatopic™ Plus Emollient Foam™ ) chosen affect area four week . Photography use record location target lesion baseline , week two week four/final visit . Subject 's disease status assess two method : 1 ) Physician 's Global Assessment ( PGA ) 2 ) Target Lesion Symptom Score ( TLSS ) ( see section V.B.2 V.B.3 ) . PGA well TLSS make baseline ( Day 0 ) , week two ( Day 14 +/- 2 day ) week 4/final visit ( Day 28 +/- 2days ) visit target lesion . Half scale ( i.e . 0.5 , 1.5 ) use . The presence absence skin atrophy telangiectasias note study visit well . Additionally , subject ' self-assessments perception degree disease itch severity control collect visit target lesion . This assessment make use four point scale Itch Severity Scale ( visual analogue score ) respectively ( see section V.B.4 ) . Lastly , subject take Product Preference Survey week 4/final visit ( Day 28 +/- 2days ) . Parents ( guardian ) moderate Product Preference Surveys subject young 12 year age .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Emollients</mesh_term>
	<criteria>Males female ≥ 2 year old . Subjects must good general health confirm medical history physical examination . Females childbearing potential must negative urine pregnancy test baseline visit agree use adequate birth control study ( barrier , oral , injection , intrauterine ) . NOTE : Postmenopausal ( amenorrheic least one year ) surgically sterile ( tubal ligation and/or hysterectomy ) consider non childbearing potential . Diagnosis atopic dermatitis least one year symptom arm , trunk , and/or leg . Subject must static Investigator 's Global Assessment ( IGA ) least 2 3 ( mildmoderate severity ) select target lesion Disease must stable slowly worsen one week prior Screening Visit , report subject . Subjects guardians must able read , sign , date inform consent , abide study restriction duration . Females pregnant , attempt conceive , breastfeed . Subjects know hypersensitivity either study drug . Subjects AD &gt; 30 % body surface area Subjects overt sign skin atrophy , telangiectasias and/or stria target area . Subjects current active skin malignancy infection . Subjects require use medication know alter course atopic dermatitis study treatment . Subjects received systemic antibiotic within 2 week . Subjects use systemic corticosteroid immunosuppressant within 28 day Screening Visit . Subjects received topical corticosteroid topical therapy ( tar , calcineurin inhibitor ) atopic dermatitis within 7 day Screening Visit . Subjects use phototherapy ( UVB , PUVA ) within 28 day Screening Visit . Subjects currently participate , previous 28 day , participate another study treatment atopic dermatitis . Subjects clinical condition may pose health risk subject involve study detrimentally affect regular followup subject .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>eczema</keyword>
	<keyword>elidel</keyword>
	<keyword>non-medicated device</keyword>
	<keyword>hylatopic plus</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>bilateral comparison study</keyword>
	<keyword>topical therapy</keyword>
</DOC>